title: Association between systemic non-criteria APS manifestations and antibody type and level: results from the Serbian national cohort study.
abstract: OBJECTIVE
  The aim of this study was to investigate the importance of aPL type and level for non-criteria-related events in APS patients.
  
  
  METHODS
  Our study included 374 patients: 260 with PAPS and 114 with APS associated with systemic lupus erythematosus (SLE).
  
  
  RESULTS
  We discovered significant connection between migraine and LA absence, livedo reticularis and aCL-IgG, skin ulcerations with aCL-IgG and anti-β2GPI-IgM, pseudovasculitis lesions with aCL-IgG, aCL-IgM and anti-β2GPI-IgM, and thrombocytopenia with aCL-IgM, aCL-IgG and anti-β2GPI-IgG. Thrombocytopenia occurred more frequently in patients with more than one aPL. In PAPS, epilepsy correlated with ß2GPI-IgM, migraine with aCL-IgM, and thrombocytopenia with aCL-IgM, aCL-IgG, anti ß2GPI-IgG and LA. Skin ulcerations occurred more frequently in IIc category patients and in patients with high levels of aCL-IgG and anti ß2GPI-IgG. Livedo reticularis was more prominent in PAPS with high levels of aCL-IgG. Significantly higher prevalence of thrombocytopenia was observed in patients with high levels of aCL-IgG and anti ß2GPI-IgG. Epilepsy was related to high levels of anti ß2GPI-IgM and thrombocytopenia in the SAPS was correlated with aCL-IgG. Skin ulcerations were more prevalent in aCL-IgM positive SAPS patients and epilepsy more frequently in SAPS patients with high levels of anti ß2GPI-IgG.
  
  
  CONCLUSIONS
  Our study showed that certain aPL type with certain level correlated with non-criteria manifestations, suggesting their predictive role.
authors.affiliation: Bezanijska Kosa University Medical Centre, Belgrade, Serbia. ljudmila_stojanovich@yahoo.com
authors.forename: Ljudmila
authors.initials: L
authors.lastname: Stojanovich
authors.forename: Milica
authors.initials: M
authors.lastname: Kontic
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Djokovic
authors.forename: Dragomir
authors.initials: D
authors.lastname: Marisavljevic
authors.forename: Nenad
authors.initials: N
authors.lastname: Ilijevski
authors.forename: Natasa
authors.initials: N
authors.lastname: Stanisavljevic
authors.forename: Zeljko
authors.initials: Z
authors.lastname: Mikovic
authors.forename: Milena
authors.initials: M
authors.lastname: Petkovic
authors.forename: Vladimir
authors.initials: V
authors.lastname: Kovcin
mesh_terms: D000328:Adult; D017153:Antibodies, Anticardiolipin / Q000097:blood; D017152:Antibodies, Antiphospholipid / Q000097:blood*; D016736:Antiphospholipid Syndrome / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology* / Q000276:immunology*; D015415:Biomarkers / Q000097:blood; D016009:Chi-Square Distribution; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D054068:Livedo Reticularis / Q000453:epidemiology / Q000276:immunology; D016682:Lupus Coagulation Inhibitor / Q000097:blood; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology* / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000453:epidemiology / Q000276:immunology; D011237:Predictive Value of Tests; D015995:Prevalence; D011446:Prospective Studies; D055771:Serbia / Q000453:epidemiology; D012883:Skin Ulcer / Q000453:epidemiology / Q000276:immunology; D013921:Thrombocytopenia / Q000453:epidemiology / Q000276:immunology; D014657:Vasculitis / Q000453:epidemiology / Q000276:immunology; D053482:beta 2-Glycoprotein I / Q000276:immunology
chemical_list: D017153:Antibodies, Anticardiolipin; D017152:Antibodies, Antiphospholipid; D015415:Biomarkers; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D016682:Lupus Coagulation Inhibitor; D053482:beta 2-Glycoprotein I